amivantamab
Start here
For patients with EGFR-mutated non-small-cell lung cancer who progress on EGFR-TKI therapy such as osimertinib, several treatment standards now coexist. The global MARIPOSA-2 trial showed that amivantamab plus platinum-pemetrexed chemotherapy improved progression-free survival over platinum-pemetrexed chemotherapy alone, leading NCCN and ESMO to make it the preferred second-line regimen. A Lancet commentary weighs whether the resulting multiplicity of standards of care reflects progress, fragmentation, or inevitability. The commentary frames the question but does not settle it; which regimen suits which patient after osimertinib failure remains an open clinical decision.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- thelancet.com[Comment] Multiple standards of care in non-small-cell lung cancer after EGFR-TKI therapy: progress, fragmentation, or inevitability?
This comment examines the progress, fragmentation, and inevitability of multiple standards of care in EGFR-mutated non-small-cell lung cancer after EGFR-TKI therapy. The global MARIPOSA-2 trial showed that amivantamab plus platinum-pemetrexed chemotherapy improved PFS over platinum-pemetrexed chemotherapy alone in patients progressing after osimertinib, and it became the preferred second-line option in NCCN and ESMO guidelines.
Heat trend for this story
Heat now 29·Peak in the comparable set 40 (Oct 24 15:00)·Change over 24h in the comparable set +3%·Participants now 7
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.